Semaglutide Improves Alzheimer's Symptoms and Restores Oxytocin in Mouse and Human Brain Models
Semaglutide improved cognition, reduced amyloid plaques and tau phosphorylation, decreased neuroinflammation, and restored oxytocin levels in both Alzheimer's mice and human brain organoids.
Quick Facts
What This Study Found
Semaglutide reduced amyloid plaques, p-Tau, and neuroinflammatory markers (GFAP, Iba1) while restoring oxytocin levels in both APP/PS1 mice (with improved cognition) and human AD brain organoids.
Key Numbers
Semaglutide improved learning and memory in behavioral tests, reduced amyloid plaque deposition, and restored oxytocin levels in APP/PS1 mice.
How They Did This
APP/PS1 transgenic Alzheimer's mice: behavioral testing (learning and memory), immunohistochemistry for amyloid plaques, GFAP, Iba1, and oxytocin. Human AD brain organoids: Aβ, p-Tau, GFAP, and oxytocin measurements after semaglutide treatment.
Why This Research Matters
Alzheimer's has no effective treatment. Semaglutide is already FDA-approved and taken by millions. If it truly protects the brain, it could be repurposed for AD much faster than developing a new drug — and the oxytocin restoration suggests a novel mechanism beyond simple anti-inflammation.
The Bigger Picture
GLP-1 drugs are being investigated for Alzheimer's in clinical trials. This study adds an unexpected finding — semaglutide restores oxytocin, a neuropeptide linked to social bonding, memory, and neuroprotection. The dual peptide story (GLP-1 drug restoring oxytocin) suggests GLP-1 agonists may have broader neuroprotective mechanisms than previously understood.
What This Study Doesn't Tell Us
APP/PS1 mice model only familial Alzheimer's (a minority of cases). Human brain organoids lack full brain architecture and connectivity. The mechanism linking semaglutide to oxytocin restoration is not fully explained. Clinical trials in AD patients are needed.
Questions This Raises
- ?How does semaglutide increase brain oxytocin — through GLP-1R signaling, anti-inflammatory effects, or another mechanism?
- ?Do Alzheimer's patients taking semaglutide for diabetes show slower cognitive decline in clinical data?
- ?Could combining semaglutide with intranasal oxytocin provide synergistic neuroprotection in AD?
Trust & Context
- Key Stat:
- Oxytocin restored Semaglutide unexpectedly increased brain oxytocin levels alongside reducing amyloid plaques and improving cognition in Alzheimer's models
- Evidence Grade:
- Moderate evidence: dual-model preclinical study (mice + human organoids) with consistent results, but no clinical data in AD patients.
- Study Age:
- Published in 2024 in Biomedicine & Pharmacotherapy. Adds to growing evidence for GLP-1 drugs in neurodegeneration.
- Original Title:
- Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models.
- Published In:
- Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 180, 117540 (2024)
- Authors:
- Zhang, Yinbing, Tang, Cheng, He, Yao, Zhang, Yingqian, Li, Qinxi, Zhang, Ting, Zhao, Bangcheng, Tong, Aiping, Zhong, Qixing, Zhong, Zhihui
- Database ID:
- RPEP-09660
Evidence Hierarchy
Frequently Asked Questions
Could semaglutide prevent or treat Alzheimer's?
In mice and human brain organoids, semaglutide reduced amyloid plaques, improved memory, and restored the neuroprotective peptide oxytocin. Clinical trials are now testing this in Alzheimer's patients. While promising, it is too early to recommend semaglutide for AD.
Why did semaglutide increase oxytocin?
This was an unexpected finding. Oxytocin is a neuropeptide that supports memory and protects brain cells. Semaglutide may restore oxytocin by reducing neuroinflammation or through direct GLP-1 receptor effects on brain regions that produce oxytocin, but the exact mechanism needs further study.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09660APA
Zhang, Yinbing; Tang, Cheng; He, Yao; Zhang, Yingqian; Li, Qinxi; Zhang, Ting; Zhao, Bangcheng; Tong, Aiping; Zhong, Qixing; Zhong, Zhihui. (2024). Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models.. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 180, 117540. https://doi.org/10.1016/j.biopha.2024.117540
MLA
Zhang, Yinbing, et al. "Semaglutide ameliorates Alzheimer's disease and restores oxytocin in APP/PS1 mice and human brain organoid models.." Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2024. https://doi.org/10.1016/j.biopha.2024.117540
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide ameliorates Alzheimer's disease and restores oxy..." RPEP-09660. Retrieved from https://rethinkpeptides.com/research/zhang-2024-semaglutide-ameliorates-alzheimers-disease
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.